Reversal of learning deficits in a Tsc2+/− mouse model of tuberous sclerosis
Open accessThe DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index; 7 of the 51 sources its claims cite were checked for support.
Abstract
Tuberous sclerosis is a single-gene disorder caused by heterozygous mutations in the TSC1 (9q34) or TSC2 (16p13.3) gene and is frequently associated with mental retardation, autism and epilepsy. Even individuals with tuberous sclerosis and a normal intelligence quotient (approximately 50%) are commonly affected with specific neuropsychological problems, including long-term and working memory deficits. Here we report that mice with a heterozygous, inactivating mutation in the Tsc2 gene (Tsc2(+/-) mice) show deficits in learning and memory. Cognitive deficits in Tsc2(+/-) mice emerged in the absence of neuropathology and seizures, demonstrating that other disease mechanisms are involved. We show that hyperactive hippocampal mammalian target of rapamycin (mTOR) signaling led to abnormal long-term potentiation in the CA1 region of the hippocampus and consequently to deficits in hippocampal-dependent learning. These deficits included impairments in two spatial learning tasks and in contextual discrimination. Notably, we show that a brief treatment with the mTOR inhibitor rapamycin in adult mice rescues not only the synaptic plasticity, but also the behavioral deficits in this animal model of tuberous sclerosis. The results presented here reveal a biological basis for some of the cognitive deficits associated with tuberous sclerosis, and they show that treatment with mTOR antagonists ameliorates cognitive dysfunction in a mouse model of this disorder.
Overview
CoChat Summary
TL;DR
Mice heterozygous for an inactivating *Tsc2* mutation show hippocampal-dependent learning and memory deficits in the absence of neuropathology or seizures, driven by hyperactive mTOR signaling that lowers the threshold for late-phase LTP. Brief rapamycin treatment in adult mice reversed both the synaptic plasticity abnormality and the behavioral deficits.
Key findings
- *Tsc2*+/− mice were impaired on three hippocampus-dependent tasks: Morris water maze probe trial (genotype × quadrant interaction *F*(3,88) = 4.763, *P* = 0.004; target crossings *F*(1,88) = 4.278, *P* = 0.0415), win-shift eight-arm radial maze across-phase errors (*F*(1,36) = 4.724, *P* = 0.0364), and context discrimination (mutants lacked context specificity). Hippocampus-independent visible-platform water maze and other behaviors (motor skills, anxiety, exploration, social approach) were normal.
- Hippocampal tuberin (Tsc2) abundance was reduced to ~75% of WT with unchanged hamartin (Tsc1), and phosphorylated S6 (Ser235/Ser236) was elevated, indicating disinhibited mTOR signaling.
- An E-LTP induction paradigm (1-s, 100-Hz tetanus) produced stable L-LTP in *Tsc2*+/− slices but decaying LTP in WT slices (measure × genotype interaction *F*(29,406) = 2.436, *P* < 0.0001; last 10 min *P* = 0.0328).
- Rapamycin reversed context discrimination deficits and water maze deficits in mutants (three-way ANOVA quadrant occupancy *F*(6,348) = 2.168, *P* = 0.0456; target crossings *F*(6,348) = 2.908, *P* = 0.0088) and reversed abnormal L-LTP; lovastatin did not rescue spatial learning. In *Tsc1*cc–αCaMKII-Cre mice, rapamycin increased survival to ~70% of Mendelian expectation, reduced brain enlargement (*P* < 0.001), and improved hindlimb clasping and ambulation (*P* < 0.001).
Methods
- Behavioral testing of *Tsc2*+/− mice (C57BL/6NCrl background, 3–6-month-old males and females) and conditional *Tsc1*cc–αCaMKII-Cre mice: hidden-platform Morris water maze (4 trials/day, 5 days, probe trial), win-shift eight-arm radial maze (8 daily sessions, 2-min delay), and context fear conditioning (three 0.75-mA shocks, tested in training vs. novel context).
- Acute hippocampal slice field recordings at Schaffer collateral–CA1 synapses (input-output, paired-pulse facilitation, LTP induced by theta burst or 1-s 100-Hz tetanus, recorded 4 h); western blots of hippocampal tuberin, hamartin, and p-S6.
- Rapamycin administered intraperitoneally (5 or 1 mg/kg daily, 3 h before training; 5 mg/kg for 5 days before fear conditioning), 200 nM in slice perfusate, or 0.2 mg/kg/day subcutaneously from postnatal day 1 in the *Tsc1* study; analyses by ANOVA and *t*-tests, *P* < 0.05 significant, experiments blind to genotype and treatment.
Limitations
- The paper states it is unclear whether rapamycin will reverse cognitive deficits caused by cerebral malformations or infantile spasms, and notes that genetic background may account for differences in social behavior between *Tsc1*+/− and *Tsc2*+/− mice and for variable expressivity of tuberous sclerosis phenotypes.
- Evident from the text: all evidence is from mouse models, so the proposed benefit of mTOR inhibitors for cognitive deficits in humans with tuberous sclerosis remains untested; the conditional *Tsc1*cc–αCaMKII-Cre analyses rest on very small surviving samples (e.g., *n* = 3 untreated and *n* = 4 rapamycin-treated mice for brain weight).
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
7 Valid · 0 Not valid · 27 Not checked · 75 Own results and interpretations
Every source the paper cites for this claim was checked and supports it.
In the paper
“In the *Tsc2*+/− mouse model, the *Tsc2* gene is disrupted by insertion of a selection cassette in its second coding exon[8](#R8).”
§ Reversal of learning deficits in a *Tsc2*+/− mouse model of tuberous sclerosis > Figure 1.
What the sources say
- Supportedcites [8] Onda, H., Lueck, A., Marks, P.W., Warren, H.B. & Kwiatkowski, D.J. Tsc2+/− mice develop tumors in multiple sites that express gelsolin and are influenced by genetic background. J. Clin. Invest. 104, 687–695 (1999). source
The Methods section 'Generation of mice with a targeted, disrupted Tsc2 gene' / 'Generation of a targeted Tsc2 allele in embryonic stem cells and mice' (p. 1 of that section) states the targeting construct was made by insertion of a neomycin resistance (Neo) selection cassette into the second coding exon of Tsc2, with clones selected using G418 and fialuridine. Passage [3] corroborates the disruption location ('As the gene was disrupted in the second coding exon'). (LLM, conf=0.95)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Here we report that mice with a heterozygous, inactivating mutation in the *Tsc2* gene (*Tsc2*+/− mice)[8](#R8) show deficits in learning and memory.”
§ Reversal of learning deficits in a *Tsc2*+/− mouse model of tuberous sclerosis > Abstract
What the sources say
- Supportedcites [8] Onda, H., Lueck, A., Marks, P.W., Warren, H.B. & Kwiatkowski, D.J. Tsc2+/− mice develop tumors in multiple sites that express gelsolin and are influenced by genetic background. J. Clin. Invest. 104, 687–695 (1999). source
The citation follows the identification of the Tsc2+/− mice, while “Here we report” presents the learning-and-memory deficits as the citing authors’ own finding. In “Generation of mice with a targeted, disrupted Tsc2 gene,” the source describes producing mice heterozygous for an inactivated Tsc2 allele. It need not report the behavioral deficits to support this identification citation. (LLM, conf=0.94)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“a null mutation of the *Pten* gene caused some of the same phenotypes described for the *Tsc1*cc–αCaMKII-Cre mice”
§ Reversal of learning deficits in a *Tsc2*+/− mouse model of tuberous sclerosis > Figure 4.
What the sources say
- Supportedcites [21] Kwon, C.H., Zhu, X., Zhang, J. & Baker, S.J. mTor is required for hypertrophy of Pten-deficient neuronal soma in vivo. Proc. Natl. Acad. Sci. USA 100, 12923–12928 (2003). source
The introductory passage (page not provided) reports that neuron-specific Pten deletion caused seizures, premature death, and neuronal hypertrophy. The Results also report seizures and ataxia in adult Pten mutant mice. The comparison with Tsc1 mice is the citing authors’ framing; this source supports the attributed Pten phenotypes. (LLM, conf=0.88)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Brain enlargement was largely due to massive neuronal hypertrophy”
§ Reversal of learning deficits in a *Tsc2*+/− mouse model of tuberous sclerosis > Figure 3.
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“this treatment reversed the context discrimination deficits of *Tsc2*+/− mice ([Fig. 3a](#F3)).”
§ Reversal of learning deficits in a *Tsc2*+/− mouse model of tuberous sclerosis > Figure 2.
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Rests on an assumption not shown here.
75 more claims
Create a free account to see all 109 claims and to verify the 7 references still open.
- Probably not a substantial claim. 20
- It may state two separate claims as one. 13
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“suggesting that tuberous sclerosis complex may be a result of the dysregulation of these processes13,69.”
From Activity-dependent neuronal signalling and autism spectrum disorder (2013) · cites this paper as [69]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Similar corrections with late-onset treatment in mice have been reported in tuberous sclerosis80 and spinocerebellar ataxia type 1 (SCA1)81.”
From Drug development for neurodevelopmental disorders: lessons learned from fragile X syndrome (2018) · cites this paper as [80]
The cited source says what the claim attributes to it.
In the citing paper
“Experimental interventions, working through diverse genetic and pharmacological mechanisms, rescue subsets of behavioral abnormalities in these mouse models (31, 43, 48–52).”
From Negative allosteric modulation of the mGluR5 receptor reduces repetitive behaviors and rescues social deficits in mouse models of autism (2012) · cites this paper as [49]
The cited source says what the claim attributes to it.
In the citing paper
“Target strategies draw from therapeutics under investigation for other neurodevelopmental disorders and hypotheses emerging from mutations in synaptic genes identified in small numbers of individuals with autism spectrum disorders (43, 49, 52).”
From Negative allosteric modulation of the mGluR5 receptor reduces repetitive behaviors and rescues social deficits in mouse models of autism (2012) · cites this paper as [49]
In the citing paper
“Ehninger et al. further demonstrated that abnormalities of LTP and deficiencies in hippocampal-dependent learning tasks in Tsc2+/- animals, in which mTOR-signaling is abnormally heightened, can be rescued by the mTOR inhibitor rapamycin.”
From Unifying Views of Autism Spectrum Disorders: A Consideration of Autoregulatory Feedback Loops (2016) · cites this paper as Ehninger et al., 2008
6 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Reversal of learning deficits in a *Tsc2*+/− mouse model of tuberous sclerosis > Figure 3.
“three-way ANOVA for quadrant occupancy with genotype and treatment as between-subjects factors and pool quadrant as within-subjects factor”
§ Reversal of learning deficits in a *Tsc2*+/− mouse model of tuberous sclerosis > Figure 3.
“genotype × treatment × quadrant interaction: *F*(6,348) = 2.168, *P* = 0.0456”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Reversal of learning deficits in a *Tsc2*+/− mouse model of tuberous sclerosis > Figure 1.
“*n* = 12 mice per genotype; two-way ANOVA for quadrant occupancy with genotype as between-subjects factor and pool quadrant as within-subjects factor”
§ Reversal of learning deficits in a *Tsc2*+/− mouse model of tuberous sclerosis > Figure 1.
“genotype × pool quadrant interaction: *F* (3,88) = 4.763, *P* = 0.004”
Citations
Cites
Hippocampus, space, and memory
Olton, D. S., Becker, J. T., & Handelmann, G. E. (1979) · Behavioral and Brain Sciences · doi:10.1017/s0140525x00062713 · Cited by 2,018
Identification of the Tuberous Sclerosis Gene TSC1 on Chromosome 9q34
Slegtenhorst, M. V., Hoogt, R. D., Hermans, C., Nellist, M., Janssen, B., Verhoef, S., Lindhout, D., Ouweland, A. V. D., Halley, D., Young, J., et al. (1997) · Science · doi:10.1126/science.277.5327.805 · Cited by 1,648
Self-citationIdentification and characterization of the tuberous sclerosis gene on chromosome 16
(1993) · Cell · doi:10.1016/0092-8674(93)90618-z · Cited by 1,645
Tang, S. J., Reis, G., Kang, H., Gingras, A.-C., Sonenberg, N., & Schuman, E. M. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.012605299 · Cited by 734
Kwiatkowski, D. J. (2002) · Human Molecular Genetics · doi:10.1093/hmg/11.5.525 · Cited by 667 · cited 1×
“To test the efficacy of rapamycin in modulating other tuberous sclerosis brain phenotypes, we studied a homozygous conditional deletion of Tsc1 in neurons of the postnatal forebrain: floxed Tsc1 mice ( Tsc1 cc”
BackgroundSelf-citationFloresco, S. B., Seamans, J. K., & Phillips, A. G. (1997) · The Journal of Neuroscience · doi:10.1523/jneurosci.17-05-01880.1997 · Cited by 626 · cited 1×
“, and because the hippocampus can contribute to working memor”
BackgroundRegulation of neuronal morphology and function by the tumor suppressors Tsc1 and Tsc2
Tavazoie, S. F., Alvarez, V. A., Ridenour, D. A., Kwiatkowski, D. J., & Sabatini, B. L. (2005) · Nature Neuroscience · doi:10.1038/nn1566 · Cited by 497 · cited 1×
“Second, Tsc1 −/− hippocampal neurons were shown to have morphological and functional synaptic abnormalitie”
BackgroundSelf-citationSancak, O., Nellist, M., Goedbloed, M., Elfferich, P., Wouters, C., Maat-Kievit, A., Zonnenberg, B., Verhoef, S., Halley, D., & van den Ouweland, A. (2005) · European Journal of Human Genetics · doi:10.1038/sj.ejhg.5201402 · Cited by 483
The dorsal hippocampus is essential for context discrimination but not for contextual conditioning.
Frankland, P. W., Cestari, V., Filipkowski, R. K., McDonald, R. J., & Silva, A. J. (1998) · Behavioral Neuroscience · doi:10.1037//0735-7044.112.4.863 · Cited by 410 · cited 1×
“Discriminating between similar contexts is known to also depend on hippocampal functio”
BackgroundSelf-citationOnda, H., Lueck, A., Marks, P. W., Warren, H. B., & Kwiatkowski, D. J. (1999) · Journal of Clinical Investigation · doi:10.1172/jci7319 · Cited by 349
Self-citation
Cited by
Items 701–800 of 860
Viewing Animal Models for Tuberous Sclerosis Complex in the Light of Evolution
Howe, C. J., Serfontein, J., Nisbet, R. E. R., & de Vries, P. J. (2014) · Neuromethods · doi:10.1007/978-1-4939-2250-5_4 · Cited by 3
Neuroinflammation in the Pathogenesis of Early Life Epileptic Encephalopathies
Salar, S., & Galanopoulou, A. S. (2017) · Elsevier eBooks · doi:10.1016/b978-0-323-53088-0.00005-1 · Cited by 2
Trifonova, E. A., Котлярова, А. А., & Kochetov, A. V. (2023) · Molecular Biology · doi:10.1134/s0026893323020206 · Cited by 2
Pais, M., Martins, J., Castelo-Branco, M. S., & Gonçalves, J. (2024) · Epilepsia Open · doi:10.1002/epi4.12955 · Cited by 2
“8,10,11 Heterozygotic Tsc2 mutations are the most prevalent and the most frequently associated with severe clinical manifestations such as epilepsy.”
BackgroundKowalczyk, M., Lee, Y., & Huang, W. (2024) · Molecular Biology of the Cell · doi:10.1091/mbc.e24-08-0366 · Cited by 2
“Together, our Tsc2 KO behavioral data are consistent with previous reports that found abnormal adult hippocampal neurogenesis in mice can alter short-term memory (Li et al. , 2023), contextual fear learning (Ehninger et al. , 2008), and exploratory behavior (Sahay et al. , 2011).”
Dysfunction of the Methyl-CpG-Binding Protein MeCP2 in Rett Syndrome
Calfa, G. D., Percy, A. K., & Pozzo‐Miller, L. D. (2012) · Springer eBooks · doi:10.1007/978-1-4614-3345-3_3 · Cited by 2
Autism In Tuberous Sclerosis: Are Risk Factors Identifiable and Preventable?
Curatolo, P., & Moavero, R. (2011) · Future Neurology · doi:10.2217/fnl.11.31 · Cited by 2
Cline, M. A., Denbow, M., Gilbert, E. R., & Dridi, S. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-819770-7.00038-4 · Cited by 2
Şahin, M., Miller, I., Holmes, G. L., & Sheth, R. D. (2011) · Epilepsy & Behavior · doi:10.1016/j.yebeh.2011.02.010 · Cited by 2
Dysregulation of TOR Signaling in Tuberous Sclerosis and Lymphangioleiomyomotosis
Yu, J. J., & Henske, E. P. (2010) · The Enzymes · doi:10.1016/s1874-6047(10)27016-6 · Cited by 2
Genetic and Pharmacological Reversibility of Phenotypes in Mouse Models of Autism Spectrum Disorder
Schroeder, J. C., Deliu, E., Novarino, G., & Schmeißer, M. J. (2017) · Advances in anatomy, embryology and cell biology · doi:10.1007/978-3-319-52498-6_10 · Cited by 2
Khairullin, A. E., Mukhamedyarov, M. A., Grishin, S. N., Teplov, A. Y., Nagiev, K. K., & Зиганшин, А. У. (2023) · BIOPHYSICS · doi:10.1134/s0006350923010086 · Cited by 2
Rat and Mouse Models of Tuberous Sclerosis
Kwiatkowski, D. J. (2010) · Wiley eBooks · doi:10.1002/9783527630073.ch7 · Cited by 2
Self-citationProtein Misfolding and Axonal Protection in Neurodegenerative Diseases
Inoue, H., Kondo, T., Lin, L., Mi, S., Isacson, O., & Takahashi, R. (2008) · Focus on structural biology · doi:10.1007/978-1-4020-9434-7_4 · Cited by 2
“Mice heterozygous for the deletion of the Tsc2 gene in Tsc2(+/−) mice show deficits in learning and memory [38].”
BackgroundInfluentialEpigenetic Therapeutic Intervention for a Rare Epilepsy Disorder
Jago, S. S., & Lubin, F. D. (2020) · Epiliepsy currents/Epilepsy currents · doi:10.1177/1535759720904162 · Cited by 2
“The 3 main categories of epigenetic markers, DNA methylation, posttranslational histone modifications, and small noncoding RNAs, are considered as central regulators of synaptic plasticity and learning and memory.(6,7) Additionally, studies have shown that dysfunctional methyl binding of proteins influences seizure ac…”
BackgroundPreclinical models for autism spectrum disorder: past, present, and future
Dwivedi, S., Rajput, P., Akhtar, A., Goli, S. H., & Dusane, A. (2025) · Neuroscience · doi:10.1016/j.neuroscience.2025.10.063 · Cited by 1
Emerging Research towards the Understanding and Treatment of Autism
Wang, P. P., Hammond, R., Postma, F. R., & Healy, A. M. (2012) · Royal Society of Chemistry eBooks · doi:10.1039/9781849734943-00384 · Cited by 1
Anti-convulsant Agents: Everolimus
Hertzberg, C., & Franz, D. N. (2022) · Springer eBooks · doi:10.1007/978-3-030-62059-2_306 · Cited by 1
Focal postnatal deletion of Tsc2 causes epilepsy
McCoy, C., Dusing, M. R., Jerow, L. G., Winstel, G. C., Zhan, F., Rogers, J. L., Wesley, M., Otten, J. B., Danzer, S. C., & LaSarge, C. L. (2025) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2025.1686023 · Cited by 2
Cipriano, G. L., Floramo, A., Argento, V., Oddo, S., & Artimagnella, O. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27010455 · Cited by 1
“Nevertheless, a large body of evidence shows that hyperactive mTOR signalling can adversely impact multiple forms of learning and memory [40,41].”
Präventive Therapie bei tuberöser Sklerose: Konzepte, Evidenz und offene Fragen
Driedger, J. H., & Syrbe, S. (2026) · Clinical Epileptology · doi:10.1007/s10309-026-00834-z · Cited by 1
Hsieh, C. C., Tsou, Y., Huang, N., Chen, T., Li, S., Chang, C.-W., Lin, W.-X., Tung, S.-Y., Chern, Y., Chen, Y. L., et al. (2026) · Journal of Biomedical Science · doi:10.1186/s12929-026-01269-4 · Cited by 1
mTOR Signaling in Cortical Network Development
Lin, T. V., & Bordey, A. (2014) · Elsevier eBooks · doi:10.1016/b978-0-12-415804-7.00015-0 · Cited by 1
Translational Control of Synaptic Plasticity and Memory
Khoutorsky, A., Gkogkas, C. G., & Sonenberg, N. (2012) · Springer eBooks · doi:10.1007/978-1-4614-3991-2_14 · Cited by 1
Molecular and Cellular Approaches to Cognitive Impairments Associated with NF1 and Other Rasopathies
Lee, Y., & Silva, A. J. (2012) · Springer eBooks · doi:10.1007/978-3-642-32864-0_37 · Cited by 1
Self-citationInvestigating Therapeutic Strategies for Fragile X Syndrome in Mice
Michalon, A., & Lindemann, L. (2012) · BioValley monographs · doi:10.1159/000339190 · Cited by 1
Regression in development after seizure onset in tuberous sclerosis: a report of two cases
Srivastava, C., & Bolton, P. (2013) · American journal of autism · doi:10.7726/aja.2013.1001 · Cited by 1
“Moreover, the cognitive and behavioural changes reported in TSC2+/mice can be reversed by treatment with rapamycin, an mTOR inhibitor, suggesting that the abnormalities arise from dysregulation of mTOR signalling (Ehninger et al., 2008).”
From Molecular Pathways to ASD Therapy: Insights from Syndromic Forms of Autism
Nicholls, L. E., Ramadas, R., & Voineagu, I. (2014) · WORLD SCIENTIFIC eBooks · doi:10.1142/9789814602167_0002 · Cited by 1
Lo‐Castro, A., & Curatolo, P. (2014) · Cited by 1
Mucke, H. A. (2012) · Pharmaceutical Patent Analyst · doi:10.4155/ppa.12.2 · Cited by 1
Bolivar, V. J. (2014) · Cambridge University Press eBooks · doi:10.1017/cbo9781107360556.012 · Cited by 1
Koike-Kumagai, M., & Wataya‐Kaneda, M. (2022) · Journal of Experimental Neurology · doi:10.33696/neurol.3.064 · Cited by 1
Mitochondrial Dysfunction and mTOR in Autism Spectrum Disorders
SELAMET, E., & Usta, M. B. (2023) · Psikiyatride Guncel Yaklasimlar - Current Approaches in Psychiatry · doi:10.18863/pgy.1205786 · Cited by 1
Khairullin, A. E., Mukhamedyarov, M. A., Grishin, S. N., Teplov, A. Y., Nagiev, K. K., & Зиганшин, А. У. (2023) · Биофизика · doi:10.31857/s0006302923010192 · Cited by 1
Rodent Models for ASD Biomarker Development
Lee, H. H. C., & Şahin, M. (2024) · Advances in neurobiology · doi:10.1007/978-3-031-69491-2_8 · Cited by 2
Behavioral analyses in rodent models of tuberous sclerosis complex
Santos, V. R., Jerow, L. G., & LaSarge, C. L. (2025) · Epilepsy & Behavior · doi:10.1016/j.yebeh.2025.110313 · Cited by 1
Sildenafil promotes dual memory effects in young rats: involvement of dopamine reuptake
Constantin, M. F., de la Villarmois, E. A., Bravo, J., Marcotti, A., Ghersi, M., Castro, F., Calfa, G. D., Rubianes, M. D., & Pérez, M. F. (2025) · Psychopharmacology · doi:10.1007/s00213-025-06806-x · Cited by 2
“These deficits include impairments in recognition memory and facilitated fear memory generalization (lack of context specificity in freezing responses) (Ehninger et al. 2008; López-Aranda et al. 2023).”
Familial Renal Cell Cancers and Pheochromocytomas
Chan–Smutko, G., & Iliopoulos, O. (2010) · Springer eBooks · doi:10.1007/978-0-387-93846-2_9 · Cited by 1
Wiedemann, C. G. (2008) · Nature reviews. Neuroscience · doi:10.1038/nrn2467 · Cited by 1
Toward targeted treatments in tuberous sclerosis
Moavero, R., Graziola, F., Romagnoli, G., & Curatolo, P. (2015) · Expert Opinion on Orphan Drugs · doi:10.1517/21678707.2016.1127158 · Cited by 1
Transgenic Mice with Enhanced Cognition
Lee, Y. (2015) · Elsevier eBooks · doi:10.1016/b978-0-12-417042-1.00005-x · Cited by 1
Social Endophenotypes in Mouse Models of Psychiatric Disease
Pisansky, M. T., Gottesman, I. I., & Gewirtz, J. C. (2016) · Springer eBooks · doi:10.1007/978-1-4939-3777-6_8 · Cited by 1
Muhle, R., Sanders, S., Reed, H. E., & State, M. W. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-800105-9.00029-9 · Cited by 1
Regulation of Synaptic Homeostasis by Translational Mechanisms
Mori, M., Penney, J., & Haghighi, A. P. (2019) · Oxford University Press eBooks · doi:10.1093/oxfordhb/9780190686307.013.14 · Cited by 1
The mTOR pathway as a therapeutic target for precision medicine
Dill, P. E., & Datta, A. (2019) · Clinical Epileptology · doi:10.1007/s10309-019-0267-5 · Cited by 1
Anticonvulsant Agents: Everolimus
Hertzberg, C., & Franz, D. N. (2020) · Springer eBooks · doi:10.1007/978-3-319-56015-1_306-1 · Cited by 2
mTOR and Cancer Therapy: General Principles
Houghton, P. J. (2009) · Humana Press eBooks · doi:10.1007/978-1-60327-271-1_6 · Cited by 1
“Interestingly, rapamycin reverses learning impairment in TSC +/– mice [ 34 ], hence may benefit TSC patients who also suffer”
BackgroundBelle, J. E. L., Condro, M. C., Cepeda, C., Oikonomou, K. D., Tessema, K. K., Dudley, L., Schoenfield, J., Kawaguchi, R., Geschwind, D. H., Silva, A. J., et al. (2026) · Nature Communications · doi:10.1038/s41467-026-74958-1 · Cited by 2
“…inhibitor, we focused our mechanistic search on rapidly modi fi able physiological and functional processes rather than the structural remodeling that longerrapamycin treatment regimensproduce 7,29,30,61 , potentially revealing mechanisms obscured by chronic dosing.”
Self-citationTuberous Sclerosis Complex and the Mammalian Target of Rapamycin Pathways
Yu, J. J. (2010) · Wiley eBooks · doi:10.1002/9780470015902.a0022388 · Cited by 1
Genetic studies of autism and autistic-like traits
Jönsson, L. (2015) · Gothenburg University Publications Electronic Archive (Gothenburg University) · Cited by 1
Transtornos do espectro autista: progredindo para melhorias em sua farmacoterapia
Suzuki, Â. M. (2013) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/d.41.2013.tde-26072013-144026 · Cited by 1
Progress Toward Therapies and Interventions for Neurodevelopmental Disorders
Ajetunmobi, A., & Tropea, D. (2015) · Wiley eBooks · doi:10.1002/9781118524947.ch14 · Cited by 1
Insights into the human Fragile X syndrome gene family using Drosophila melanogaster
Coffee, R. L. (2011) · Cited by 2
Ouyang, T., Zhang, N., Benjamin, T., Wang, L., Jiao, J., Zhao, Y., & Chen, J. (2016) · Child s Nervous System · doi:10.1007/s00381-016-3047-9 · Cited by 1
RetractedAlzheimer, C. (2021) · Pflügers Archiv - European Journal of Physiology · doi:10.1007/s00424-021-02584-5 · Cited by 1
“Importantly, the human disease phenotype is well reproduced in TSC mouse models [4, 8].”
BackgroundSpence, S., & Sahin, M. (2012) · Springer eBooks · doi:10.1007/978-1-4419-1698-3_207 · Cited by 1
CHARACTERIZING AND TREATING THE NEUROPATHOLOGY OF TUBEROUS SCLEROSIS COMPLEX IN THE MOUSE
Way, S. W. (2010) · Digital Commons-TMC (Texas Medical Center)
CHARACTERIZATION AND TREATMENT OF A NOVEL MOUSE MODEL OF TSC-ASSOCIATED AUTISM
Reith, R. M. (2012) · Digital Commons-TMC (Texas Medical Center)
The Role of the E3 Ubiquitin Ligases Nedd4-1 and Nedd4-2 in Synaptic Transmission and Plasticity
Takeda, M. (2013) · eDiss (Georg-August-Universität Göttingen) · doi:10.53846/goediss-3862
Clifford, M. A. (2012) · Georgetown University-Graduate School of Arts & Sciences
Kalogerou, M. (2013) · ORCA Online Research @Cardiff (Cardiff University)
Understanding the Etiology of Tuberous Sclerosis Complex
Bordey, A. (2012) · Defense Technical Information Center (DTIC) · doi:10.21236/ada566455
Goorden, S. M. I. (2012) · EUR Research Repository (Erasmus University Rotterdam)
The role of TSC2 and deptor in fetal cortical development
Tsai, V. (2012) · ScholarlyCommons (University of Pennsylvania)
mTOR inhibition as a therapeutic strategy in tuberous sclerosis or sporadic lymphangioleiomyomatosis
Davies, D. M. (2011) · ORCA Online Research @Cardiff (Cardiff University) · Cited by 1
The management of drug resistant seizures in tuberous sclerosis
Curatolo, P., Bombardieri, R., Pinci, M., & Moavero, R. (2009) · Journal of Pediatric Sciences · doi:10.17334/jps.81324
Pathology and treatment of autism spectrum disorders
Kotajima‐Murakami, H., Sato, A., & Ikeda, K. (2015) · Folia Pharmacologica Japonica · doi:10.1254/fpj.145.193
Social phenotypes in genetic syndromes
Swillen, A., de Ravel, T. J. L., & Oliver, C. (2012) · Journal of Intellectual Disability Research · doi:10.1111/j.1365-2788.2012.01620.x · Cited by 1
Correction: Stochastic Model of Tsc1 Lesions in Mouse Brain
Prabhakar, S., Goto, J., Zhang, X., Sena‐Esteves, M., Bronson, R. T., Brockmann, J., Gianni, D., Wojtkiewicz, G. R., Chen, J. W., Stemmer-Rachamimov, A. O., et al. (2013) · PLoS ONE · doi:10.1371/annotation/6a5b0a50-27e4-49bc-b82a-9267dd63af53
Self-citationThe future of genetics in everyday medicine
Thalayasingam, N. (2009) · The Journal of the Royal College of Physicians of Edinburgh · doi:10.4997/jrcpe.2009.413
Kamm, C. (2013) · Clinical Investigation · doi:10.4155/cli.13.45
Behandelingen voor genetische neurocognitieve aandoeningen
Overwater, I. E., van der Vaart, T., de Wit, M. Y., Oostenbrink, R., & Elgersma, Y. (2013) · Neuropraxis · doi:10.1007/s12474-013-0025-9
“Muizen heterozygoot voor TSC1 of TSC2 hebben hierdoor problemen met leren en geheugen, bijvoorbeeld in de Morris Water Maze-taak die eerder beschreven werd (Goorden et al., 2007; Ehninger et al., 2008).”
BackgroundFamilies with neurocutaneous syndromea - Report of two cases
Saha, R., Mahmud, R., Hossain, M. Z., & Sarkar, P. K. (2013) · Journal of Dhaka Medical College · doi:10.3329/jdmc.v22i1.15709
Childhood Disorders of the Synapse: Challenges and Opportunities
HUGHES, V. A., Sheng, M., & Zoghbi, H. Y. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3004356
Social dysfunction and mental retardation
Pietropaolo, S., Sluyter, F., & Crusio, W. E. (2014) · Cambridge University Press eBooks · doi:10.1017/cbo9781107360556.010 · Cited by 1
Bibliography: regarding Treatment-Based Approaches in Autism
Mumper, E. A., Binstock, T., & Johnson, J. C. (2009)
Rubeis, S. D. (2010) · Cineca Institutional Research Information System (Tor Vergata University) · doi:10.58015/de-rubeis-silvia_phd2010-01-14
Yanos, M. E. (2014) · ResearchWorks at the University of Washington (University of Washington)
Targeting mTOR: A Little Bit of History and a Large Future
Rowinsky, E. K. (2015) · Springer eBooks · doi:10.1007/978-2-8178-0492-7_1
Wilson, N. R., & Sur, M. (2011) · The MIT Press eBooks · doi:10.7551/mitpress/9780262015233.003.0007
Mouse Models of Tuberous Sclerosis
Ehninger, D. (2014) · Neuromethods · doi:10.1007/978-1-4939-2250-5_17 · Cited by 1
Self-citationNew Indications of mTOR Inhibitors in Rare Tumors
Shah, G., Stergiopoulos, S. G., & Lebwohl, D. (2015) · Springer eBooks · doi:10.1007/978-2-8178-0492-7_6
Targeting the PI3K/Akt/mTOR pathway in traumatic brain injury and developmental disease
Nikolaeva, I. (2016) · doi:10.7282/t3cz39bh · Cited by 2
Novel cognitive impairments identified in a Drosophila model of Neurofibromatosis Type 1
Vose, L. R. (2012) · ProQuest Demo Repository
Behavioral Analysis and Rescue of a Novel Cerebellar Mouse Model of Tuberous Sclerosis Complex
Gambello, M. J. (2012) · Defense Technical Information Center (DTIC) · doi:10.21236/ada566012
Central Nervous System Nutrient-sensing and the Regulation of Energy and Glucose Homeostasis
Lam, K. L. C. (2010) · TSpace (University of Toronto)
New Perspectives in Autism Spectrum Disorder associated with Tuberous Sclerosis
Benvenuto, A., Graziola, F., Moavero, R., Mazzone, L., Gialloreti, L. E., Curatolo, P., & Siracusano, M. (2017) · Journal of Pediatric Neurology · doi:10.1055/s-0037-1601445
Intracellular Pathways Associated with the Etiology of Autism
Russo, A. J. (2017) · InTech eBooks · doi:10.5772/67206 · Cited by 1
“For mTOR over‐activation, the mTORC1 inhibitor rapamycin has shown promising results in PTEN KO mice [119] and TSC2 mice [131].”
BackgroundType II Diabetes and Metabolic Syndrome as Risk Factors for Alzheimer’s Disease
Farooqui, A. A. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-809937-7.00005-7
Regulation of Local Translation, Synaptic Plasticity, and Cognitive Function by CNOT7
McFleder, R. L. (2017) · The Journal of the American Medical Association (JAMA) Network (American Medical Association) · doi:10.13028/m2km3r
“Interestingly, the ASD-like phenotypes in models of both of these mutations can be abolished with the application of mTORC1 inhibitors, demonstrating the contribution of aberrant mTORC1 activity to neurological dysfunction (Ehninger et al., 2008, Zhou et al., 2009a, Meikle et al., 2008).”
BackgroundTargeting Unselective Autophagy of Cellular Aggregates
Seneci, P. (2015) · Elsevier eBooks · doi:10.1016/b978-0-12-801944-3.00004-7
“In vivo testing of rapamycin shows therapeutic effects against cancer [33], obesity [34], cerebral ischemia [35], food allergy [36], muscular dystrophy [37], autism [38], and kidney diseases [39].”
BackgroundNon-motor symptoms in Parkinson’s disease : modeling and mechanisms
Masini, D. (2018) · Figshare
Emerging treatments and therapeutic targets for tuberous sclerosis complex in children
Słowińska, M., & Jóźwiak, S. (2019) · Expert Opinion on Orphan Drugs · doi:10.1080/21678707.2019.1662295
Wang, B., Dong, R., Xu, L., Sun, X., Chen, H., Zhou, J., Li, X., Wang, M., & Bi, Y. (2019) · Cognitive and Behavioral Neurology · doi:10.1097/wnn.0000000000000205
“Another study demonstrated that mTOR might also contribute to the pathogenesis of cognitive dysfunction and neurologic deficits in neurodegenerative diseases (Ehninger et al, 2008).”
Background雅, 水. (2018) · 児童青年精神医学とその近接領域 · doi:10.20615/jscap.59.4_363
Genetics of autism spectrum disorders
Gupta, A. R., Fernandez, T. V., & Hoffman, E. J. (2020) · doi:10.1093/med/9780198713005.003.0028
Dysregulated Translation in Autism Spectrum Disorder
Santini, E., & Borgkvist, A. (2020) · Oxford University Press eBooks · doi:10.1093/oxfordhb/9780190686307.013.24
mTOR-Autophagy: A Key for Geniposide Protection in APP/PS1 Transgenic Mice
Zhang, Z., Gao, W., Wang, X., Zhang, D., Liu, Y., Wang, X., & Li, L. (2020) · Vide Leaf, Hyderabad eBooks · doi:10.37247/paaging.1.2020.1
“Inhibition of mTOR was shown to reverse learning deficits in Tsc2+/− mice [33], and memory deficits induced by delta-9tetrahydro-cannabinol in normal mice [34].”
BackgroundNonlinear Measure of EEG Complexity in the Eker Rat model of Autism Disorder
Knocikova, J. A., Vejmola, Č., Klovrza, O., & Petrásek, T. (2020) · International Conference on Mathematics and Statistics (ICoMS) · doi:10.1145/3409915.3409927
Mammalian target of rapamycin complexes
Querfurth, H. W., & Lee, H. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-815868-5.00021-9
Metadata
- Authors
- Ehninger, D., Han, S., Shilyansky, C., Zhou, Y., Li, W., Kwiatkowski, D. J., Ramesh, V., & Silva, A. J.
- Affiliations
- University of California, Los Angeles (US)
- Harvard University (US)
- Brigham and Women's Hospital (US)
- Corresponding author
- Silva, Alcino J
- Venue
- Nature Medicine
- Published
- 2008-06-22
- Volume
- 14
- Issue
- 8
- Pages
- 843-848
- ISSN
- 1078-8956 (ISSN-L)
- 1546-170X
- PMC
- PMC2664098
- OpenAlex
- W1989779456
- Cited by
- 882
- References
- 30
- Citations by year
- 2026: 22 · 2025: 24 · 2024: 23 · 2023: 28 · 2022: 31 · 2021: 40 · 2020: 48 · 2019: 37 · 2018: 40 · 2017: 46 · 2016: 55 · 2015: 76 · 2014: 61 · 2013: 73 · 2012: 90
- FWCI
- 44.38
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Medicine (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- Autism Speaks (AS1862)
- National Institute of Neurological Disorders and Stroke (R01NS038480, P01NS024279)
- Topics
- Health Sciences › Medicine › Genetics (clinical) › Tuberous Sclerosis Complex Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetics and Neurodevelopmental Disorders
- Keywords
- tuberous sclerosis complex, mTOR signaling, hippocampal long-term potentiation, hippocampus-dependent learning, spatial learning deficits, contextual discrimination, cognitive impairment, rapamycin, mTOR inhibitors, synaptic plasticity, autism spectrum disorder, intellectual disability
- MeSH terms
- Tuberous Sclerosis Complex 2 Protein, Animals, Behavior, Animal, Cognition Disorders, Female, Heterozygote, Hippocampus, Learning, Male, Mice, Inbred C57BL, Protein Kinases, Tuberous Sclerosis, Signal Transduction, Sirolimus, Tumor Suppressor Proteins, Mice, TOR Serine-Threonine Kinases
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-11-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-11-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (qwen3.8-omni-flash and gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.